Cis-diamminedichloroplatinum (NSC-119875) : a phase i study
Higby, D.J.; Wallace, H.J.; Holland, J.F.
Cancer ChemoTherapy Reports 57(4): 459-463
1973
ISSN/ISBN: 0069-0112 PMID: 4586953 Document Number: 5089
Forty-five patients with intractable malignant disease were treated with cis-diamminedichloroplatinum. Nausea and vomiting occurred at all dose levels of the drug. At the higher dose levels, sporadic white blood cell count and platelet count depressions were seen. Tinnitus and high-frequency hearing Joss occurred in four patients. At dose levels of 24 mg/m2 given daily for 5 days or 100 mg/m2 given daily for 1 day, creatinine elevations consistently occurred, and in a few cases the elevations were prolonged or irreversible. Postmortem examination revealed that renal tubular necrosis had occurred in two patients within 1 month of drug administration, and tubular swelling was noted in a third patient. Tumor regressions were seen in one patient with breast cancer, one with transitional cell carcinoma of the bladder, one with anaplastic (small cell) thyroid carcinoma, and nine of 11 patients with testicular tumors. The schedule chosen for phase II studies was 20 mg/m2 of cis-diamminedichloroplatinum given daily for 5 days every 4 weeks, if the renal, hematologic, and auditory functions permitted.
Document emailed within 1 workday
